Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-MPV and Reduced-Dose WBRT for PCNSL
NCT00594815Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2002
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in primary central nervous system lymphoma (PCNSL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Total Number of Participants Who Experienced Acute Treatment Related Adverse Events at 2 years and Progression Free Survival at 2 years. Started Aug 2002; status: completed.
02
Drugs
rituximab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT00594815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00594815.